NDA 050547 · Sterimax
Claforan
Cefotaxime Sodium · Injection
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Mar 11, 1981
Approved uses
2
Original approval plus efficacy supplements
Registered trials
214
60 Phase 3, 18 recruiting
FAERS reports
5,624
5,523 serious, 1,079 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 14, 2026.
INDICATIONS AND USAGE Treatment CLAFORAN is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae , Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species , Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections. Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 27, 1996 Supplement 42 · Efficacy
- Mar 11, 1981 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
- CLAFORAN · CEFOTAXIME SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
- CLAFORAN · CEFOTAXIME SODIUM EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- CLAFORAN · CEFOTAXIME SODIUM EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- CLAFORAN · CEFOTAXIME SODIUM EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefotaxime" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe PneumoniaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT04041791 · 4,392 participants · Start Aug 19, 2019 · Primary completion Apr 5, 2024
Drug: Benzyl penicillin; Gentamicin Sulfate and 3 more · For: Pneumonia
Sites: Machakos, Kenya
- PRophylaxis Against Early VENTilator-associated Infections in Acute Brain InjuryPivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06819592 · 3,300 participants (planned) · Start Oct 30, 2025 · Primary completion Aug 2029
Drug: Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride; Placebo comparator - no ceftriaxone · For: All-cause Mortality; Quality of Life; Disability, Intellectual and 4 more
Sites: Canberra, Australia; Camperdown, Australia; Darlinghurst, Australia · 29 sites in all
- Prehospital Antibiotics Against Sepsis TrialPivotal-lookingCompleted
Amsterdam UMC, location VUmcAcademic, hospital or other
NCT01988428 · 2,672 participants · Start Jun 2014 · Primary completion Jun 2017
Drug: Ceftriaxone 2000 mg · For: Sepsis; Severe Sepsis; Septic Shock
Sites: Amstelveen, Netherlands; Amersfoort, Netherlands; Amsterdam, Netherlands · 34 sites in all
- The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)Pivotal-lookingCompleted
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT04349826 · 2,150 participants · Start May 23, 2021 · Primary completion Dec 31, 2025
Drug: Azithromycin; Cefixime and 1 more · For: Typhoid Fever
Sites: Lalitpur, Nepal
- Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)Pivotal-lookingCompleted
Dr. Damon ScalesAcademic, hospital or other
NCT03068741 · 2,061 participants · Start Mar 23, 2020 · Primary completion Nov 17, 2025
Drug: Comparison 1: Prehospital Ceftriaxone; Comparison 1: Placebo and 2 more · For: Severe Sepsis or Septic Shock
Sites: Toronto, Canada · 4 sites in all
- Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal SurgeryPivotal-lookingStatus unknown
Poitiers University HospitalAcademic, hospital or other
NCT05755789 · 2,000 participants (planned) · Start Jun 22, 2023 · Primary completion May 2025
Drug: Loading bolus of cefoxitin; Intermittent cefoxitin and 3 more · For: Antibiotic Prophylaxis; Colorectal Surgery
Sites: Poitiers, France; Angers, France; Arras, France · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia406
- drug ineffective381
- off label use349
- drug reaction with eosinophilia and systemic symptoms276
- acute kidney injury256
- thrombocytopenia219
- neutropenia197
- rash182
- toxic epidermal necrolysis177
- sepsis174
- condition aggravated169
- diarrhoea164
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 101 |
| 2005 | 111 |
| 2006 | 81 |
| 2007 | 133 |
| 2008 | 97 |
| 2009 | 138 |
| 2010 | 94 |
| 2011 | 190 |
| 2012 | 198 |
| 2013 | 175 |
| 2014 | 186 |
| 2015 | 228 |
| 2016 | 228 |
| 2017 | 249 |
| 2018 | 395 |
| 2019 | 448 |
| 2020 | 617 |
| 2021 | 473 |
| 2022 | 399 |
| 2023 | 373 |
| 2024 | 316 |
| 2025 | 243 |
| 2026 | 148 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lyme Neuroborreliosis.
Rauer S, Kastenbauer S, Fingerle V, et al. · Dtsch Arztebl Int 2018 · Systematic Review
- Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial.
Reyman M, van Houten MA, Watson RL, et al. · Nat Commun 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Antibiotic resistance rates in hypervirulent Klebsiella pneumoniae strains: A systematic review and meta-analysis.
Beig M, Aghamohammad S, Majidzadeh N, et al. · J Glob Antimicrob Resist 2024 · Meta-Analysis, Systematic Review
- Efficacy and safety of antibiotics for treatment of leptospirosis: a systematic review and network meta-analysis.
Ji Z, Jian M, Su X, et al. · Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, et al. · BMC Infect Dis 2023 · Systematic Review, Network Meta-Analysis
- Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
Sort P, Navasa M, Arroyo V, et al. · N Engl J Med 1999 · Clinical Trial, Randomized Controlled Trial
Sponsor: Sterimax
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.